603 related articles for article (PubMed ID: 33586682)
1. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
2. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
Shen T; Dong B; Meng Y; Moore DD; Yang F
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
[TBL] [Abstract][Full Text] [Related]
3. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
Wang W; Shen T; Dong B; Creighton CJ; Meng Y; Zhou W; Shi Q; Zhou H; Zhang Y; Moore DD; Yang F
J Clin Invest; 2019 Mar; 129(3):1015-1029. PubMed ID: 30688659
[TBL] [Abstract][Full Text] [Related]
4. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
5. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
7. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
[TBL] [Abstract][Full Text] [Related]
9. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
11. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
12. Role of protein S in castration-resistant prostate cancer-like cells.
Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
[TBL] [Abstract][Full Text] [Related]
13. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
14. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
16. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
19. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
20. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
[Next] [New Search]